Drug news

Torisel (Pfizer) fails in combination trial with Avastin in Renal Cell Carcinoma

Read time: 1 mins

Last updated:11th Aug 2012

Published:11th Aug 2012

Source: Pharmawand

Pfizer Inc. announced that the Phase III INTORACT trial (B1771006), evaluating the combination of bevacizumab plus Torisel (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-?-2a) in the first-line treatment of patients with advanced Renal Cell Carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population. Additional efficacy endpoints and safety data for the combination treatments in both arms are being analyzed and will be presented at an upcoming major medical congress.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation for Tofidence (tocilizumab biosimilar)

Biogen Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Tofidence (tocilizumab), a biosimilar monoclonal antibody referencing Rocactemra

1 mins

Drug news

New data show Rinvoq (upadacitinib) demonstrated superiority versus Dupixent (dupilumab) across primary and all secondary endpoints in an open-label head-to-head atopic dermatitis study

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of upadacitinib (Rinvoq, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (Dupixent, per its labeled dose) in adults and adolescents (greater than 12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable

2 min

Drug news

FDA approves Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections

Utility Therapeutics received approval from the FDA for Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus

1 min

See all news